<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta http-equiv="Content-Style-Type" content="text/css" /><meta name="generator" content="Aspose.Words for .NET 13.4.0.0" /><title>Written evidence submitted by Cancer Research UK (RAD001)</title></head><body><div><p style="margin:0pt"><span style="font-family:'Trebuchet MS'; font-size:11pt">&#xa0;</span></p><p style="margin:5pt 0pt; text-align:center"><span style="display:none; font-family:Calibri; font-size:11pt">Written evidence to the inquiry into Research and Development funding for science and technology in the UK Written evidence to the inquiry into Research and Development funding for science and technology in the UK Written evidence to the inquiry into </span><span style="display:none; font-family:Calibri; font-size:11pt">Research and Development funding for science and technology in the UK Written evidence to the inquiry into Research and Development funding for science and technology in the UK Written evidence to the inquiry into Research and Development funding for scien</span><span style="display:none; font-family:Calibri; font-size:11pt">ce and technology in the UKWritten evidence to the inquiry into Research and Development funding for science and technology in the UKWritten evidence to the inquiry into Research and Development funding for science and technology in the UK</span><span style="font-family:Calibri; font-size:11pt; font-weight:bold">Written evidence </span><span style="font-family:Calibri; font-size:11pt; font-weight:bold">submitted by Cancer Research UK (RAD001)</span></p><ol type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:Calibri; font-size:11pt; font-weight:normal; margin:5pt 0pt 6pt 31.2pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">Every year around 300,000 people are diagnosed with cancer in the UK. Every year more than 150,000 people die from cancer. Cancer Research UK is the worl</span><span style="font-family:Calibri; font-size:11pt">d’s </span><span style="font-family:Calibri; font-size:11pt">largest</span><span style="font-family:Calibri; font-size:11pt"> cancer charity</span><span style="font-family:Calibri; font-size:11pt"> and is</span><span style="font-family:Calibri; font-size:11pt"> dedicated to saving lives through research. </span><span style="font-family:Calibri; font-size:11pt">Together with our partners and supporters, Cancer Research UK's vision is to bring forward the day when all cancers are cured. We support research into all aspects of cancer thro</span><span style="font-family:Calibri; font-size:11pt">ugh the work of over 4,000 scientists, doctors and nurses.</span><span style="font-family:Calibri; font-size:11pt"> In 2012/13, we spent over £</span><span style="font-family:Calibri; font-size:11pt">330</span><span style="font-family:Calibri; font-size:11pt"> million on research in institutes, hospitals and universities across the UK. The charity’s pioneering work has been at the heart of the progress that has already seen</span><span style="font-family:Calibri; font-size:11pt"> survival rates in the UK double in the last forty years. We receive no </span><span style="font-family:Calibri; font-size:11pt">G</span><span style="font-family:Calibri; font-size:11pt">overnment funding for our research.</span></li><li style="font-family:Calibri; font-size:11pt; font-weight:normal; margin:5pt 0pt 6pt 31.2pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">Cancer Research UK funds research into all aspects of cancer from</span><span style="font-family:Calibri; font-size:11pt">&#xa0;</span><span style="font-family:Calibri; font-size:11pt">exploratory biology to clinical trials of novel and existing drugs as well as epi</span><span style="font-family:Calibri; font-size:11pt">demiological studies and prevention research. We support research in a variety of different environments, including university research groups, core funded Institutes and  Cancer Research UK Centres. </span><span style="font-family:Calibri; font-size:11pt">We welcome the National Audits Office (NAO’s) report on </span><span style="font-family:Calibri; font-size:11pt">the current state of R&amp;D funding as useful for demonstrating the levels of investment </span><span style="font-family:Calibri; font-size:11pt">into </span><span style="font-family:Calibri; font-size:11pt">Research and Development</span><span style="font-family:Calibri; font-size:11pt"> </span><span style="font-family:Calibri; font-size:11pt">(R&amp;D) </span><span style="font-family:Calibri; font-size:11pt">over the last 18 years.</span><span style="font-family:Calibri; font-size:11pt"> </span><span style="font-family:Calibri; font-size:11pt">The report supports previous published evidence that a</span><span style="font-family:Calibri; font-size:11pt"> </span><span style="font-family:Calibri; font-size:11pt">sustained guarantee </span><span style="font-family:Calibri; font-size:11pt">of</span><span style="font-family:Calibri; font-size:11pt"> future investment in research </span><span style="font-family:Calibri; font-size:11pt">from </span><span style="font-family:Calibri; font-size:11pt">Government</span><span style="font-family:Calibri; font-size:11pt"> </span><span style="font-family:Calibri; font-size:11pt">provides confidence f</span><span style="font-family:Calibri; font-size:11pt">or industry to invest in the UK. This investment particularly in medical research </span><span style="font-family:Calibri; font-size:11pt">delivers clear and substantial improvements in the health of the UK population.</span><a name="_ftnref1"></a><a href="#_ftn1">[1]</a><span style="font-family:Calibri; font-size:11pt">  </span><span style="font-family:Calibri; font-size:11pt">Cancer Research UK recently released a report </span><span style="font-family:Calibri; font-size:11pt; font-style:italic">Working t</span><span style="font-family:Calibri; font-size:11pt; font-style:italic">ogether: the impact of medical research investment on the health and wealth of the nation</span><span style="font-family:Calibri; font-size:11pt"> which demonstrated the impact of Government investment </span><span style="font-family:Calibri; font-size:11pt">in</span><span style="font-family:Calibri; font-size:11pt"> research.</span><a name="_ftnref2"></a><a href="#_ftn2">[2]</a><span style="font-family:Calibri; font-size:11pt"> </span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:Calibri; font-size:11pt; font-variant:small-caps">Recent </span><span style="font-family:Calibri; font-size:11pt; font-variant:small-caps">Government</span><span style="font-family:Calibri; font-size:11pt; font-variant:small-caps"> Spending Reviews</span></p><ol start="3" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:Calibri; font-size:11pt; font-weight:normal; margin:0pt 0pt 6pt 31.35pt; padding-left:4.65pt; text-align:justify; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">Canc</span><span style="font-family:Calibri; font-size:11pt">er Research UK </span><span style="font-family:Calibri; font-size:11pt">was</span><span style="font-family:Calibri; font-size:11pt"> supportive of the Government’s decision</span><span style="font-family:Calibri; font-size:11pt">s</span><span style="font-family:Calibri; font-size:11pt"> in the 2010 and 2013 spending reviews to maintain </span><span style="font-family:Calibri; font-size:11pt">a flat cash settlement for </span><span style="font-family:Calibri; font-size:11pt">the £4.6 billion </span><span style="font-family:Calibri; font-size:11pt">science </span><span style="font-family:Calibri; font-size:11pt">budget</span><span style="font-family:Calibri; font-size:11pt">. </span><span style="font-family:Calibri; font-size:11pt">We also welcomed that </span><span style="font-family:Calibri; font-size:11pt">the</span><span style="font-family:Calibri; font-size:11pt"> ring fence </span><span style="font-family:Calibri; font-size:11pt">for the science budget </span><span style="font-family:Calibri; font-size:11pt">was maintained within </span><span style="font-family:Calibri; font-size:11pt">the </span><span style="font-family:Calibri; font-size:12pt">Department of </span><span style="font-family:Calibri; font-size:12pt">Business, Innovation and Skills</span><span style="font-family:Calibri; font-size:11pt"> </span><span style="font-family:Calibri; font-size:11pt">to ensure that spending continue</span><span style="font-family:Calibri; font-size:11pt">s</span><span style="font-family:Calibri; font-size:11pt"> to be focused on research. </span></li><li style="background-color:#ffffff; font-family:Calibri; font-size:11pt; font-weight:normal; margin:5pt 0pt 0pt 31.2pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">With</span><span style="font-family:Calibri; font-size:11pt"> </span><span style="font-family:Calibri; font-size:11pt">public finances severely stretched,</span><span style="font-family:Calibri; font-size:11pt"> and</span><span style="font-family:Calibri; font-size:11pt"> other </span><span style="font-family:Calibri; font-size:11pt">Government</span><span style="font-family:Calibri; font-size:11pt"> </span><span style="font-family:Calibri; font-size:11pt">departments </span><span style="font-family:Calibri; font-size:11pt">experiencing</span><span style="font-family:Calibri; font-size:11pt"> real term</span><span style="font-family:Calibri; font-size:11pt">s</span><span style="font-family:Calibri; font-size:11pt"> cuts, we are pleased that </span><span style="font-family:Calibri; font-size:11pt">science has been protected and,</span><span style="font-family:Calibri; font-size:11pt"> indeed</span><span style="font-family:Calibri; font-size:11pt">, will see </span><span style="font-family:Calibri; font-size:11pt">increases in spending on infrastructure and equipment</span><span style="font-family:Calibri; font-size:11pt"> until 2020.</span></li><li style="background-color:#ffffff; font-family:Calibri; font-size:11pt; font-weight:normal; margin:0pt 0pt 0pt 31.2pt; padding-left:4.5pt; text-align:justify; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">Cancer Research UK and others in the sector</span><span style="font-family:Calibri; font-size:11pt"> will continue to make the case to Government why increasing the amount spent on research is beneficial to both patients and the economy</span><span style="font-family:Calibri; font-size:11pt">. </span><span style="font-family:Calibri; font-size:11pt">We are jointly funding work </span><span style="font-family:Calibri; font-size:11pt">which will demonstrate the value of </span><span style="font-family:Calibri; font-size:11pt">G</span><span style="font-family:Calibri; font-size:11pt">overnment investment in medical research and also a project which </span><span style="font-family:Calibri; font-size:11pt">looks at the interdependencies of research funders in the UK.</span><span style="font-family:Calibri; font-size:11pt"> Both reports will be ava</span><span style="font-family:Calibri; font-size:11pt">ilable by the end of this year.</span><span style="font-family:Calibri; font-size:11pt"> </span><span style="font-family:Calibri; font-size:11pt">We </span><span style="font-family:Calibri; font-size:11pt"> believe </span><span style="font-family:Calibri; font-size:11pt">it would be worthwhile for the</span><span style="font-family:Calibri; font-size:11pt"> committee </span><span style="font-family:Calibri; font-size:11pt">to </span><span style="font-family:Calibri; font-size:11pt">explor</span><span style="font-family:Calibri; font-size:11pt">e</span><span style="font-family:Calibri; font-size:11pt"> how increasing spend on science in the longer term could yield even greater health and wealth benefit.</span></li></ol><p style="background-color:#ffffff; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:Calibri; font-size:11pt">&#xa0;</span></p><p style="background-color:#ffffff; margin:0pt 0pt 0pt 35.7pt; text-align:justify"><span style="font-family:Calibri; font-size:11pt">&#xa0;</span></p><p style="background-color:#ffffff; margin:0pt 0pt 0pt 36pt; text-align:justify"><img src="data:image/png;base64,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" width="600" height="196" alt="" style="margin-left:30.5pt; margin-top:0.55pt; position:absolute; z-index:3" /><span style="font-family:Calibri; font-size:11pt; font-weight:bold">RECOMMENDATION 1: Committee inquiry on science spending</span></p><p style="background-color:#ffffff; margin:0pt 0pt 6pt 36pt; text-align:justify"><span style="font-family:Calibri; font-size:11pt">Government should produce a plan o</span><span style="font-family:Calibri; font-size:11pt">utlining how it will support</span><span style="font-family:Calibri; font-size:11pt"> science in the long-term. Th</span><span style="font-family:Calibri; font-size:11pt">is</span><span style="font-family:Calibri; font-size:11pt"> should incorporate spending decisions on all elements of publicly funded research including infrastructure</span><span style="font-family:Calibri; font-size:11pt">. This will help provide certainty for future funding decisions by both commercial and non</span><span style="font-family:Calibri; font-size:11pt">-commercial funders. Medical research in particular is a long-term endeavour that requires sustained and stable funding in order for basic research to be translated into technologies that benefit patients. It can take decades for medical research to develo</span><span style="font-family:Calibri; font-size:11pt">p into treatments, much longer than the 4-5 year spending review periods that Government currently adopts. The Committee should investigate the merits of such a plan and advise on </span><span style="font-family:Calibri; font-size:11pt">possible content and </span><span style="font-family:Calibri; font-size:11pt">a suitable length.</span></p><p style="margin:5pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span><img src="data:image/png;base64,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" width="600" height="157" alt="" style="margin-left:30.5pt; margin-top:15.7pt; position:absolute; z-index:4" /></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:Calibri; font-size:11pt; font-weight:bold">RECOMMENDATION 2: Committee </span><span style="font-family:Calibri; font-size:11pt; font-weight:bold">inquiry into the distribution of the current science budget</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:Calibri; font-size:11pt">The academic and charitable sector welcomed the Government’s announcements of a flat cash settlement in the 2013 spending review. How money is allocated within the science ring fence will be of pa</span><span style="font-family:Calibri; font-size:11pt">rticular interest to the sector</span><span style="font-family:Calibri; font-size:11pt">,</span><span style="font-family:Calibri; font-size:11pt"> including how the outcome of the research councils’ triennial review affects the settlement. </span><span style="font-family:Calibri; font-size:11pt"> Investigating</span><span style="font-family:Calibri; font-size:11pt"> how to effectively allocate the science budget could be a potentially useful inquiry for the science and technology</span><span style="font-family:Calibri; font-size:11pt"> committee.</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:Calibri; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:Calibri; font-size:11pt; font-variant:small-caps">Comments on the NAO report</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:Calibri; font-size:11pt">The following section contrasts the findings of the NAO report with Cancer Research UK’s ex</span><span style="font-family:Calibri; font-size:11pt">perience of funding UK research.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:Calibri; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:Calibri; font-size:11pt; font-style:italic">Diversity of funding</span></p><ol start="6" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:Calibri; font-size:11pt; font-weight:normal; margin:0pt 0pt 6pt 31.35pt; padding-left:4.65pt; text-align:justify; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">The NAO report demonstrates how Not</span><span style="font-family:Calibri; font-size:11pt">-f</span><span style="font-family:Calibri; font-size:11pt">or</span><span style="font-family:Calibri; font-size:11pt">-</span><span style="font-family:Calibri; font-size:11pt">Profits have contributed to </span><span style="font-family:Calibri; font-size:11pt">the increased investment in Higher Education Institutions but does not go further into explaining the importance of a diversity of different types of funder and the advantages they bring to R&amp;D taking place in the UK.</span><a name="_ftnref3"></a><a href="#_ftn3">[3]</a><span style="font-family:Calibri; font-size:11pt"> </span></li><li style="font-family:Calibri; font-size:11pt; font-weight:normal; margin:0pt 0pt 6pt 31.35pt; padding-left:4.65pt; text-align:justify; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">Government investment into R&amp;D</span><span style="font-family:Calibri; font-size:11pt"> not o</span><span style="font-family:Calibri; font-size:11pt">nly provides its own direct economic returns but more importantly</span><span style="font-family:Calibri; font-size:11pt"> provides the foundation on which charities, industry and other funders invest in research</span><span style="font-family:Calibri; font-size:11pt">. It is Government funding</span><span style="font-family:Calibri; font-size:11pt">,</span><span style="font-family:Calibri; font-size:11pt"> through bodies such as the Medical Research Council (MRC)</span><span style="font-family:Calibri; font-size:11pt">,</span><span style="font-family:Calibri; font-size:11pt"> </span><span style="font-family:Calibri; font-size:11pt"> the</span><span style="font-family:Calibri; font-size:11pt"> National </span><span style="font-family:Calibri; font-size:11pt">Institute for Health Research (NIHR)</span><span style="font-family:Calibri; font-size:11pt"> and</span><span style="font-family:Calibri; font-size:11pt"> the</span><span style="font-family:Calibri; font-size:11pt"> Higher Education Funding Council for England</span><span style="font-family:Calibri; font-size:11pt"> </span><span style="font-family:Calibri; font-size:11pt">(HEFCE) </span><span style="font-family:Calibri; font-size:11pt">that ensure that the UK has a world leading medical research sector.</span><span style="font-family:Calibri; font-size:11pt"> It is the UK’s traditional strength in life sciences that makes the UK attractive in the </span><span style="font-family:Calibri; font-size:11pt">global marketplace. </span></li><li style="font-family:Calibri; font-size:11pt; font-weight:normal; margin:0pt 0pt 6pt 31.35pt; padding-left:4.65pt; text-align:justify; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">In 2011</span><span style="font-family:Calibri; font-size:11pt"> we commissioned </span><span style="font-family:Calibri; font-size:11pt">the Office for Health Economics </span><span style="font-family:Calibri; font-size:11pt">(OHE) </span><span style="font-family:Calibri; font-size:11pt">to </span><span style="font-family:Calibri; font-size:11pt">produce a report</span><span style="font-family:Calibri; font-size:11pt">,</span><span style="font-family:Calibri; font-size:11pt"> </span><span style="font-family:Calibri; font-size:11pt; font-style:italic">Exploring the interdependencies between Public and Charitable Medical Research</span><span style="font-family:Calibri; font-size:11pt; font-style:italic">,</span><span style="font-family:Calibri; font-size:11pt"> which provided further evidence on the need for Government investment in research</span><span style="font-family:Calibri; font-size:11pt">.</span><a name="_ftnref4"></a><a href="#_ftn4">[4]</a><span style="font-family:Calibri; font-size:11pt"> In the report the OHE concluded that:</span></li></ol><p style="margin:0pt 0pt 6pt 72pt; text-align:justify"><span style="font-family:Calibri; font-size:11pt">“</span><span style="font-family:Calibri; font-size:11pt">Wholly independent and self-sufficient medical research initiatives are rare. Arguably all research activity depends, to a greater </span><span style="font-family:Calibri; font-size:11pt">or lesser extent, on other parts of the total medical research “ecology” in the UK, and in many cases, internationally. </span><span style="font-family:Calibri; font-size:11pt">For example, universities conducting charity-funded projects also receive infrastructure support from the public sector through QR and t</span><span style="font-family:Calibri; font-size:11pt">he CRSF.”</span></p><ol start="9" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:Calibri; font-size:11pt; font-weight:normal; margin:0pt 0pt 6pt 31.35pt; padding-left:4.65pt; text-align:justify; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">The report provides additional evidence on the effects of “Crowding In” and “Crowding Out” and the need for continued funding to support</span><span style="font-family:Calibri; font-size:11pt"> existing infrastructure:</span></li><li style="font-family:Calibri; font-size:11pt; font-weight:normal; margin:0pt 0pt 6pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">“The argument for crowding in is that changes in Government funding flows can affec</span><span style="font-family:Calibri; font-size:11pt">t charities’ funding flows and vice versa. If, for example, Government funding of medical research decreases (increases) and this causes donors to increase (decrease) their own contributions to medical research charities, then Government funding and privat</span><span style="font-family:Calibri; font-size:11pt">e donations are substitutes. This effect is identified in the literature as “crowding-out”. If, however, decreases (increases) in Government funding lead to decreases (increases) in private contributions to charities, then the two sources of medical resear</span><span style="font-family:Calibri; font-size:11pt">ch funding are complements and there is a “crowding-in” effect.”</span></li><li style="font-family:Calibri; font-size:11pt; font-weight:normal; margin:0pt 0pt 6pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">This message from the </span><span style="font-family:Calibri; font-size:11pt">OHE </span><span style="font-family:Calibri; font-size:11pt">research  was largely mirrored in the Department for Business, Innovation and Skills report “</span><span style="font-family:Calibri; font-size:11pt">Leverage from public funding of science and research”</span><span style="font-family:Calibri; font-size:11pt"> which demonstrated the value of Government investment </span><span style="font-family:Calibri; font-size:11pt">through attracted additional investment from both commercial and non-commercial sources</span><span style="font-family:Calibri; font-size:11pt">.</span><a name="_ftnref5"></a><a href="#_ftn5">[5]</a><span style="font-family:Calibri; font-size:11pt"> </span><span style="font-family:Calibri; font-size:11pt">The following case study </span><span style="font-family:Calibri; font-size:11pt">shows </span><span style="font-family:Calibri; font-size:11pt">the value of investment for commercial, public and non-commercial funders.</span><span style="font-family:Calibri; font-size:11pt"> </span></li></ol><p style="margin:0pt 0pt 6pt; text-align:justify"><span style="font-family:Verdana; font-size:12pt">&#xa0;</span><img src="data:image/png;base64,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" width="659" height="330" alt="" style="margin-left:-9pt; margin-top:10.95pt; position:absolute; z-index:0" /></p><p style="margin:0pt 0pt 6pt 36pt; text-align:justify"><span style="font-family:Calibri; font-size:11pt; font-weight:bold">CASE STUDY: </span><span style="font-family:Calibri; font-size:11pt; font-weight:bold">STRATIFIED MEDICINE</span></p><ol start="12" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:Calibri; font-size:11pt; font-weight:normal; margin:0pt 0pt 6pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">In partnership with the Government funded Technology Strategy Board, Pfizer and Astra Zeneca, Cancer Research UK is undertaking an ambitious programme to lay the foundations for stratified medicine development and treatment </span><span style="font-family:Calibri; font-size:11pt">in the UK. Stratified medicine will allow patients to receive targeted treatments. </span></li><li style="font-family:Calibri; font-size:11pt; font-weight:normal; margin:0pt 0pt 6pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">The programme is testing tumour samples from 9,000 patients across six different tumour types to help </span><span style="font-family:Calibri; font-size:11pt">establish the foundations for a national service that will ensure stan</span><span style="font-family:Calibri; font-size:11pt">dardised, high quality, cost-effective genetic testing of tumours is available for people with cancer.  Ultimately this has the aim of also helping further research into new targeted therapies</span><span style="font-family:Calibri; font-size:11pt">. The programme requires collaboration between universities, hos</span><span style="font-family:Calibri; font-size:11pt">pitals and commercial industry to support the infrastructure of collecting tumour samples.</span></li><li style="font-family:Calibri; font-size:11pt; font-weight:normal; margin:0pt 0pt 6pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">As a direct result of the programme, two pharmaceutical companies, Roche and Bristol-Myers Squibb, are working with Cancer Research UK to set up trials in the UK </span><span style="font-family:Calibri; font-size:11pt">that draw on this information. Doctors will be able to use the database to see if any of their patients have specific faults in their tumour identified through the stratified medicine programme, which might make them suitable to join the companies’ trials.</span></li></ol><p style="margin:0pt 0pt 6pt; text-align:justify"><span style="font-family:Verdana; font-size:11pt">&#xa0;</span></p><p style="background-color:#ffffff; margin:0pt 0pt 6pt 36pt; text-align:justify"><br style="page-break-before:always; clear:both" /><span style="font-family:Calibri; font-size:11pt; font-weight:bold">RECOMMENDATION 3</span><span style="font-family:Calibri; font-size:11pt; font-weight:bold"> Committee inquiry on diversity of funding</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><img src="data:image/png;base64,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" width="584" height="176" alt="" style="margin-left:20.75pt; margin-top:-30.4pt; position:absolute; z-index:1" /><span style="font-family:Calibri; font-size:11pt">The NAO report highlights the importance of the Not</span><span style="font-family:Calibri; font-size:11pt">-f</span><span style="font-family:Calibri; font-size:11pt">or</span><span style="font-family:Calibri; font-size:11pt">-</span><span style="font-family:Calibri; font-size:11pt">Profit sector in the UK research environment. </span><span style="font-family:Calibri; font-size:11pt">We know that the diversity of funding is a unique element to the UK and brings about signifi</span><span style="font-family:Calibri; font-size:11pt">cant advantages.</span><a name="_ftnref6"></a><a href="#_ftn6">[6]</a><span style="font-family:Calibri; font-size:11pt"> </span><span style="font-family:Calibri; font-size:11pt">The Committee may wish to consider an inquiry into the relationship between Government, industry and Not</span><span style="font-family:Calibri; font-size:11pt">-f</span><span style="font-family:Calibri; font-size:11pt">or</span><span style="font-family:Calibri; font-size:11pt">-</span><span style="font-family:Calibri; font-size:11pt">Profits for the R&amp;D in the UK and whether there are any additional measures that Government could be taking to ensure that </span><span style="font-family:Calibri; font-size:11pt">collaboration takes place and that Not</span><span style="font-family:Calibri; font-size:11pt">–f</span><span style="font-family:Calibri; font-size:11pt">or</span><span style="font-family:Calibri; font-size:11pt">-</span><span style="font-family:Calibri; font-size:11pt">Profits can invest their money most effectively.  </span></p><p style="margin:0pt 0pt 6pt 36pt; text-align:justify"><span style="font-family:Calibri; font-size:11pt">&#xa0;</span></p><p style="margin:5pt 0pt 0pt 36pt; text-align:justify"><img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAkkAAACKCAYAAAC+Y94HAAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAADsMAAA7DAcdvqGQAAAd1SURBVHhe7dhBasNQEAVB3f/SNrZAWCDD23cZAjGZzdT8RZPjOD8vPwy8AW/AG/AGvAFvwBv4voHrc/vy+we/EyBAgAABAgSCAlcbiaTg9a1MgAABAgQI/BUQSR4HAQIECBAgQOBBQCR5FgQIECBAgAABkeQNECBAgAABAgQ2Af9J2pxMESBAgAABAjEBkRQ7uHUJECBAgACBTUAkbU6mCBAgQIAAgZiASIod3LoECBAgQIDAJiCSNidTBAgQIECAQExAJMUObl0CBAgQIEBgExBJm5MpAgQIECBAICYgkmIHty4BAgQIECCwCYikzckUAQIECBAgEBMQSbGDW5cAAQIECBDYBETS5mSKAAECBAgQiAmIpNjBrUuAAAECBAhsAiJpczJFgAABAgQIxAREUuzg1iVAgAABAgQ2AZG0OZkiQIAAAQIEYgIiKXZw6xIgQIAAAQKbgEjanEwRIECAAAECMQGRFDu4dQkQIECAAIFNQCRtTqYIECBAgACBmIBIih3cugQIECBAgMAmIJI2J1MECBAgQIBATEAkxQ5uXQIECBAgQGATEEmbkykCBAgQIEAgJiCSYge3LgECBAgQILAJiKTNyRQBAgQIECAQExBJsYNblwABAgQIENgERNLmZIoAAQIECBCICYik2MGtS4AAAQIECGwCImlzMkWAAAECBAjEBERS7ODWJUCAAAECBDYBkbQ5mSJAgAABAgRiAiIpdnDrEiBAgAABApuASNqcTBEgQIAAAQIxAZEUO7h1CRAgQIAAgU1AJG1OpggQIECAAIGYgEiKHdy6BAgQIECAwCYgkjYnUwQIECBAgEBMQCTFDm5dAgQIECBAYBMQSZuTKQIECBAgQCAmIJJiB7cuAQIECBAgsAmIpM3JFAECBAgQIBATEEmxg1uXAAECBAgQ2ARE0uZkigABAgQIEIgJiKTYwa1LgAABAgQIbAIiaXMyRYAAAQIECMQERFLs4NYlQIAAAQIENgGRtDmZIkCAAAECBGICIil2cOsSIECAAAECm4BI2pxMESBAgAABAjEBkRQ7uHUJECBAgACBTUAkbU6mCBAgQIAAgZiASIod3LoECBAgQIDAJiCSNidTBAgQIECAQExAJMUObl0CBAgQIEBgExBJm5MpAgQIECBAICYgkmIHty4BAgQIECCwCYikzckUAQIECBAgEBMQSbGDW5cAAQIECBDYBETS5mSKAAECBAgQiAmIpNjBrUuAAAECBAhsAiJpczJFgAABAgQIxAREUuzg1iVAgAABAgQ2AZG0OZkiQIAAAQIEYgIiKXZw6xIgQIAAAQKbgEjanEwRIECAAAECMQGRFDu4dQkQIECAAIFNQCRtTqYIECBAgACBmIBIih3cugQIECBAgMAmIJI2J1MECBAgQIBATEAkxQ5uXQIECBAgQGATEEmbkykCBAgQIEAgJiCSYge3LgECBAgQILAJiKTNyRQBAgQIECAQExBJsYNblwABAgQIENgERNLmZIoAAQIECBCICYik2MGtS4AAAQIECGwCImlzMkWAAAECBAjEBERS7ODWJUCAAAECBDYBkbQ5mSJAgAABAgRiAiIpdnDrEiBAgAABApuASNqcTBEgQIAAAQIxAZEUO7h1CRAgQIAAgU1AJG1OpggQIECAAIGYgEiKHdy6BAgQIECAwCYgkjYnUwQIECBAgEBMQCTFDm5dAgQIECBAYBMQSZuTKQIECBAgQCAmIJJiB7cuAQIECBAgsAmIpM3JFAECBAgQIBATEEmxg1uXAAECBAgQ2ARE0uZkigABAgQIEIgJiKTYwa1LgAABAgQIbAIiaXMyRYAAAQIECMQERFLs4NYlQIAAAQIENgGRtDmZIkCAAAECBGICIil2cOsSIECAAAECm4BI2pxMESBAgAABAjEBkRQ7uHUJECBAgACBTUAkbU6mCBAgQIAAgZiASIod3LoECBAgQIDAJiCSNidTBAgQIECAQExAJMUObl0CBAgQIEBgExBJm5MpAgQIECBAICYgkmIHty4BAgQIECCwCYikzckUAQIECBAgEBMQSbGDW5cAAQIECBDYBETS5mSKAAECBAgQiAmIpNjBrUuAAAECBAhsAiJpczJFgAABAgQIxAREUuzg1iVAgAABAgQ2AZG0OZkiQIAAAQIEYgIiKXZw6xIgQIAAAQKbgEjanEwRIECAAAECMQGRFDu4dQkQIECAAIFNQCRtTqYIECBAgACBmIBIih3cugQIECBAgMAmIJI2J1MECBAgQIBATEAkxQ5uXQIECBAgQGATEEmbkykCBAgQIEAgJiCSYge3LgECBAgQILAJiKTNyRQBAgQIECAQExBJsYNblwABAgQIENgERNLmZIoAAQIECBCICYik2MGtS4AAAQIECGwCImlzMkWAAAECBAjEBERS7ODWJUCAAAECBDYBkbQ5mSJAgAABAgRiAiIpdnDrEiBAgAABApuASNqcTBEgQIAAAQIxAZEUO7h1CRAgQIAAgU3gFkmfL34YeAPegDfgDXgD3oA3cL4BHwIECBAgQIAAgSeBN0KUlrA1VHmCAAAAAElFTkSuQmCC" width="584" height="137" alt="" style="margin-left:20.75pt; margin-top:3.5pt; position:absolute; z-index:2" /><span style="font-family:Calibri; font-size:11pt; font-weight:bold">RECOMMENDATION 4: Committee inquiry on higher education R&amp;D spending</span></p><p style="margin:5pt 0pt 6pt 36pt; text-align:justify"><span style="font-family:Calibri; font-size:11pt">The NAO report outlines the real term</span><span style="font-family:Calibri; font-size:11pt">s</span><span style="font-family:Calibri; font-size:11pt"> decrease in public sector spending in research in Hi</span><span style="font-family:Calibri; font-size:11pt">gher Education Institutes. The committee could consider reviewing the impact of </span><span style="font-family:Calibri; font-size:11pt">Government</span><span style="font-family:Calibri; font-size:11pt"> investment in higher education R&amp;D and look at the possible outcomes for increasing or decreasing investment in these areas</span><span style="font-family:Calibri; font-size:11pt">, especially the knock on effects for inve</span><span style="font-family:Calibri; font-size:11pt">stment by commercial and non-commercial entities</span><span style="font-family:Calibri; font-size:11pt">.</span><a name="_ftnref7"></a><a href="#_ftn7">[7]</a></p><p style="margin:0pt 0pt 6pt 36pt; text-align:justify"><span style="font-family:Calibri; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 6pt 36pt; text-align:justify"><span style="font-family:Calibri; font-size:11pt; font-style:italic">Regional Spending</span></p><ol start="15" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:Calibri; font-size:11pt; font-weight:normal; margin:0pt 0pt 6pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">The NAO report notes that 89% of R&amp;D expenditure take</span><span style="font-family:Calibri; font-size:11pt">s</span><span style="font-family:Calibri; font-size:11pt"> place in the South East of England. While spending may typically be focused in this location especially due to the concentration of world class universities in Oxford, Cambridge and London, </span><span style="font-family:Calibri; font-size:11pt">Cancer Research UK</span><span style="font-family:Calibri; font-size:11pt"> can demonstrate that investment outside of thi</span><span style="font-family:Calibri; font-size:11pt">s area is vitally important to the overall research output of the UK. Cancer Research UK spent over £91 million outside of the South East last year in research institutions across the UK</span><span style="font-family:Calibri; font-size:11pt"> out of a budget of £330 million</span><span style="font-family:Calibri; font-size:11pt">.</span><span style="font-family:Calibri; font-size:11pt"> </span><span style="font-family:Calibri; font-size:11pt">T</span><span style="font-family:Calibri; font-size:11pt">wo of our</span><span style="font-family:Calibri; font-size:11pt"> five</span><span style="font-family:Calibri; font-size:11pt"> institutes are based</span><span style="font-family:Calibri; font-size:11pt"> </span><span style="font-family:Calibri; font-size:11pt"> in Glasgow and Manchester and many of our research centres are located in major cities outside of the South East.</span><span style="font-family:Calibri; font-size:11pt"> </span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:Calibri; font-size:11pt; font-style:italic">European Framework Funding</span></p><ol start="16" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:Calibri; font-size:11pt; font-weight:normal; margin:0pt 0pt 6pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">We receive no Government funding for our research but some researchers we fund may receive funding from other </span><span style="font-family:Calibri; font-size:11pt">sources, such as EU Framework Programme fund</span><span style="font-family:Calibri; font-size:11pt">ing. Cancer Research UK’s five core funded institutes have attracted funding from EU research budgets, currently there is £37.7 million worth of EU grants in these institutes.</span></li><li style="font-family:Calibri; font-size:11pt; font-weight:normal; margin:5pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">Research depends on co-operation across scientific communities internationally. With cancer research and treatments becoming increasingly specialised, it is necessary for international teams to engage in collaborative working to share knowledge </span><span style="font-family:Calibri; font-size:11pt">and</span><span style="font-family:Calibri; font-size:11pt"> also to</span><span style="font-family:Calibri; font-size:11pt"> </span><span style="font-family:Calibri; font-size:11pt">identify</span><span style="font-family:Calibri; font-size:11pt"> the number patients necessary to run clinical studies. EU legislation can promote harmonisation</span><span style="font-family:Calibri; font-size:11pt"> to ease the setting up of multi-state trials, </span><span style="font-family:Calibri; font-size:11pt">international cooperation</span><span style="font-family:Calibri; font-size:11pt"> and sharing of best practice and knowledge</span><span style="font-family:Calibri; font-size:11pt">.</span></li><li style="font-family:Calibri; font-size:11pt; font-weight:normal; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">The EU </span><span style="font-family:Calibri; font-size:11pt">provides a </span><span style="font-family:Calibri; font-size:11pt">substantial amou</span><span style="font-family:Calibri; font-size:11pt">nt of research</span><span style="font-family:Calibri; font-size:11pt"> funding</span><span style="font-family:Calibri; font-size:11pt">, as well as supporting cooperation and data sharing. The UK is the primary beneficiar</span><span style="font-family:Calibri; font-size:11pt">y</span><span style="font-family:Calibri; font-size:11pt"> of EU research funding</span><span style="font-family:Calibri; font-size:11pt"> for health</span><span style="font-family:Calibri; font-size:11pt"> </span><span style="font-family:Calibri; font-size:11pt">which is welcome</span><span style="font-family:Calibri; font-size:11pt">.</span><span style="font-family:Calibri; font-size:11pt"> W</span><span style="font-family:Calibri; font-size:11pt">hile Cancer Research UK does not </span><span style="font-family:Calibri; font-size:11pt">directly </span><span style="font-family:Calibri; font-size:11pt">receive EU funding, </span><span style="font-family:Calibri; font-size:11pt">we acknowledge that such fundin</span><span style="font-family:Calibri; font-size:11pt">g</span><span style="font-family:Calibri; font-size:11pt"> </span><span style="font-family:Calibri; font-size:11pt">supports the wider research environment in the UK.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:Calibri; font-size:11pt">&#xa0;</span></p><ol start="19" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:Calibri; font-size:11pt; font-weight:normal; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">Overall we </span><span style="font-family:Calibri; font-size:11pt">welcome the analysis of R&amp;D spend by the NAO and believe that the data presented will be useful in highlighting trends </span><span style="font-family:Calibri; font-size:11pt">in R&amp;D investment </span><span style="font-family:Calibri; font-size:11pt">into </span><span style="font-family:Calibri; font-size:11pt">which</span><span style="font-family:Calibri; font-size:11pt"> the House </span><span style="font-family:Calibri; font-size:11pt">o</span><span style="font-family:Calibri; font-size:11pt">f Commons S</span><span style="font-family:Calibri; font-size:11pt">cience and Tech</span><span style="font-family:Calibri; font-size:11pt">nology Committee can </span><span style="font-family:Calibri; font-size:11pt"> investigate further</span><span style="font-family:Calibri; font-size:11pt">.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:Calibri; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 6pt; text-align:justify"><span style="font-family:Calibri; font-size:11pt; font-style:italic">August 2013</span></p><p style="margin:0pt"><span style="font-family:'Trebuchet MS'; font-size:11pt">&#xa0;</span></p></div><hr style="width:33%; height:1px; text-align:left" /><p style="font-size:10pt; line-height:115%; margin:0pt"><a name="_ftn1"></a><a href="#_ftnref1">[1]</a><span style="font-family:Calibri; font-size:10pt"> Department </span><span style="font-family:Calibri; font-size:10pt">of Business, Innovation and Skills,  Leverage from public funding of science and research, March 2013 p.5</span></p><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt"><a name="_ftn2"></a><a href="#_ftnref2">[2]</a><span style="font-family:Calibri; font-size:10pt"> Cancer Research UK, </span><span style="font-family:Calibri; font-size:10pt">Working together: the impact of medical research investment on the health and wealth of the </span><span style="font-family:Calibri; font-size:10pt">nation</span><span style="font-family:Calibri; font-size:10pt"> </span><a href="http://www.cancerresearchuk.org/prod_consump/groups/cr_common/@nre/@pol/documents/generalcontent/cr_109616.pdf"><span style="color:#0000ff; font-family:Calibri; font-size:10pt; text-decoration:underline">http://www.cancerresearchuk.org/prod_consump/groups/cr_common/@nre/@pol/documents/generalcontent/cr_109616.pdf</span></a><span style="font-family:Calibri; font-size:10pt"> </span></p><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt"><a name="_ftn3"></a><a href="#_ftnref3">[3]</a><span style="font-family:Calibri; font-size:10pt"> National</span><span style="font-family:Calibri; font-size:10pt"> Audit Office, </span><span style="font-family:Calibri; font-size:10pt">Research and Development funding for science and technology</span><span style="font-family:Calibri; font-size:10pt">,p.21</span></p><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt"><a name="_ftn4"></a><a href="#_ftnref4">[4]</a><span style="font-family:Calibri; font-size:10pt"> Office for </span><span style="font-family:Calibri; font-size:10pt">Health Economics, Exploring the Interdependency between Public and Charitable Medical Research, </span><a href="http://www.ohe.org/publications/article/exploring-the-interdependency-between-public-and-charitable-medical-research-6.cfm"><span style="color:#0000ff; font-family:Calibri; font-size:10pt; text-decoration:underline">http://www.ohe.org/publications/article/exploring-the-interdependency-between-public-and-charitable-medical-research-6.cfm</span></a><span style="font-family:Calibri; font-size:10pt"> </span></p><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt"><a name="_ftn5"></a><a href="#_ftnref5">[5]</a><span style="font-family:Calibri; font-size:10pt"> Department of Business, Innovation and Skills, Leverage from</span><span style="font-family:Calibri; font-size:10pt"> public funding of science and research, March 2013 p.5</span></p><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt"><a name="_ftn6"></a><a href="#_ftnref6">[6]</a><span style="font-family:Calibri; font-size:10pt"> </span><span style="font-family:Calibri; font-size:10pt">Department of Business, Innovation and Skills,</span><span style="font-family:Calibri; font-size:10pt"> </span><span style="font-family:Calibri; font-size:10pt">, Leverage from public funding of science and research, March 2013</span></p><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt"><a name="_ftn7"></a><a href="#_ftnref7">[7]</a><span style="font-family:Calibri; font-size:10pt"> National Audit Office, </span><span style="font-family:Calibri; font-size:10pt">Research and Development funding for science and technology</span><span style="font-family:Calibri; font-size:10pt">, p.21</span></p></body></html>